Life sciences genius with the ability to quickly unpick the most arcane biochemistry issues - IAM Patent 1000, United Kingdom

Daniel is a partner in Kirkland's IP litigation team in London. Daniel has a broad practice which covers a wide range of technical fields, but is particularly noted for his experience in life science patent litigation, particularly in the pharmaceutical industry, diagnostics and the emerging fields of precision medicine and cell and gene therapy. He is also experienced in representing clients involved in complex SEP and FRAND licensing disputes.

In addition to UK litigation, Daniel is regularly called upon to assist clients in devising, coordinating and executing patent strategies for complex multijurisdictional disputes at a pan-European and global scale. With dual qualifications in law and biochemistry, and experience litigating in both Australia and Europe, Daniel is readily able to grasp highly technical material and the international dimensions of disputes which are often at the heart of effective strategies in blockbuster litigation for the most sophisticated clients. In recognition of his experience and leadership in the life sciences field, Daniel currently serves as the Vice-Chair of AIPPI’s standing committee on biotechnology.

A strong believer in the power of scientific innovation to improve society and quality of life, and the role of intellectual property in incentivising and protecting such innovation, Daniel often represents leading companies in a wide range of industries for whom such innovation is core to their business.

Daniel has developed a particular interest and expertise in the rising gene editing technology CRISPR, and is recognised as a thought leader and regular writer, speaker and commentator on the topic. Daniel's previous case experience covers a broad range of technical fields, including dynamic scheduling and resource allocation in radio networks, time division multiple access (TDMA) radio signaling, laser engineering, oncology, immunology, neurology, ophthalmology, molecular diagnostics, formulation science, pharmacokinetics, clinical pharmacology and biostatistics.

Daniel is recognised as a World Intellectual Property Review Leader 2021 and is listed in IAM Strategy 300 and IAM Patent 2021. He was further recognised as a Rising Star in Life Sciences by Expert Guides in 2021 and was winner in the UK and Life Sciences categories at the Euromoney Legal Media Group Europe Rising Stars Awards 2019. Daniel was also recognized as a Rising Star by Managing Intellectual Property in both 2017 and 2018.

Daniel has spent time on secondment in-house to the generic arm of a leading global pharmaceutical company, and spent a year as Associate to Justice Yates of the Federal Court of Australia. Prior to joining Kirkland, Daniel was a lawyer at Australian top tier firm Clayton Utz, and senior associate at magic circle firm Allen & Overy.


Thought Leadership


“Trade Secrets 2022: Law and Practice”, Chambers and Partners Practice Guides, 28 April 2022 

"Trade Secrets 2020: Law and Practice,” Chambers and Partners Practice Guides, 28 April 2020

“Crunch Time (Part 1),” Intellectual Property Magazine, 28 February 2020

“Patent Litigation 2020: Trends and Developments,” Chambers and Partners Practice Guides, 10 February 2020

“CRISPR picture (Part 1),” Intellectual Property Magazine, 24 January 2020

Co-author of UK chapter in “Antibody Patenting: A Practitioner's Guide to Drafting, Prosecution and Enforcement”, AIPPI Law Series published by Wolters Kluwer, 2019

The future of precision medicine part 7: public engagement”, Life Sciences Intellectual Property Review, 29 August 2019

The future of precision medicine part 6: reimbursement”, Life Sciences Intellectual Property Review, 8 August 2019

The future of precision medicine part 5: keeping pace with regulation”, Life Sciences Intellectual Property Review, 26 July 2019

“How to empower young IP lawyers to be leaders”, Managing Intellectual Property, 24 July 2019

“Patent Litigation 2019: Trends and Developments”, Chambers and Partners Practice Guides, 20 June 2019

Academia in the City: Bridging the gap between legal theory and practice”, Per Incuriam, 15 February 2019

The future of precision medicine part 4: diagnosing the diagnostic problem”, Life Sciences Intellectual Property Review, 14 February 2019

“Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?”, European Journal of Human Genetics, 19 December 2018

Patents, platform technologies and new therapeutic modalities”, IAM, 30 November 2018

Four patent lessons the tech sector can teach life sciences companies”, IAM, 2 November 2018

The four big trends that will transform life sciences patent strategies”, IAM, 1 November 2018

The future of precision medicine part 3: translation from research to the clinic”, Life Sciences Intellectual Property Review, 23 October 2018

The future of precision medicine part 2: data is king”, Life Sciences Intellectual Property Review, 17 July 2018

The future of precision medicine part 1: challenges and opportunities”, Life Sciences Intellectual Property Review, 13 June 2018

“Disruption and development: the evolving CRISPR patent and technology landscape”, Pharmaceutical Patent Analyst, 8 June 2018

“More than Just a Game (Report 3): Loot boxes and gambling”, IP Kat, 22 February 2018

“More than Just a Game (Report 2): Music, video games, GDPR & technical protective measures”, IP Kat, 22 February 2018

“More than Just a Game (Report 1): eSports”, IP Kat, 17 February 2018

“Patent suits mount up but CRISPR industry rolls on regardless”, Intellectual Property Magazine, 26 January 2018

“CRISPR Update part 1 – Crowded field”, Intellectual Property Magazine, 5 December 2017

“Questions about CRISPR”, Intellectual Property Magazine, 29 March 2017

“AIPPI Congress Report 5: Antitrust and Pharma - seeking a balance”, IP Kat, 29 November 2016

“AIPPI Congress Report 2: AIPPI for the uninitiated – day 1 as a conference ingénue”, IP Kat, 18 September 2016


Speaker, “International Patent Litigation: UK Sufficiency of Disclosure”, European Summit on Pharma & Biotech Patent Litigation, 15 March 2022

Panellist, “Claims to antibodies - practical tips and tricks from a UK perspective”, Global Biologics, Cell and Gene Legal Summit, 15 June 2022

Panellist, “British perspectives on FRAND”, OxViews 7th Intellectual Property and Competition Forum, 22 June 2022

Speaker, “FRAND Valuation and Pricing” - Standards and Patents: Law and Litigation Conference, 7 July 2022 

Moderator, “Forensics in biotech litigation”, AIPPI Virtual World Congress, 20 October 2021

Moderator, “Reaping the fruits of wise prosecution when litigating BioPharma patents”, AIPPI Virtual World Congress, 19 October 2021

Panellist, Chambers Global Practice Guides: IP Authors Networking V-Meet, 6 October 2021

Panellist, “Global Licensing Considerations Involving CRISPR/Cas9”, Licensing Executives Society USA & Canada Annual Meeting, 27 September 2021

Moderator, “Innovator v Innovator Litigation”, AIPPI World Congress, 13 October 2020

Speaker and workshop leader, “Developing a Robust Trade Secret Framework Within Your Organisation”, C5 Pharma & Biotech Patent Litigation Conference, 24 February 2020

Moderator, “Brexit and IP: an update”, AIPPI World Congress – London, 17 September 2019

Moderator, “Patent litigation strategies in advance of the launch of new biologic medicine”, Managing IP International Patent Forum panel, 6 March 2019

“Somatic gene editing: Legal and regulatory aspects – what is needed to launch genome editing in the clinic?”, European Society of Human Genetics, 18 June 2018

“CRISPR’s IP licensing landscape”, Intellectual Property Magazine Webinar, 5 December 2017

“CRISPR: Legal and regulatory considerations”, CRISPRcon table talk, 16 August 2017

Press Coverage

Quoted “Major CRISPR patent decision won’t end tangled dispute”, Nature Portfolio, 9 March 2022

Quoted “So, just how much are those CRISPR patents actually worth?”, Endpoints News, 8 March 2022

Quoted “Broad Institute’s big US CRISPR patent win does little to clear path for Cas9 licensees”, IAM, 3 March 2022

Quoted “Pharma should make good use of the UPC from the beginning, says Bayer’s head of IP”, IAM, 11 August 2021

Quoted “DABUS: legal team reveals winning strategy and long-term hopes”, Managing Intellectual Property, 5 August 2021

Quoted “How to overcome antimicrobial resistance IP challenges”, Managing Intellectual Property, 24 June 2021 

Quoted “How the EPO’s latest CRISPR revocation affects the Cas9 landscape”, IAM, 1 April 2021

Quoted “Virtual trials creating hurdles for expert witness testimony”, Managing Intellectual Property, 28 January 2021

Quoted “EU GMO Directive ‘stunts’ CRISPR patents,” Managing Intellectual Property, 14 January 2021

Quoted “Combatting Covid-19,” Intellectual Property Magazine, 29 October 2020

Quoted “Lawyer reactions: Unwired Planet ‘brings certainty’,” Intellectual Property Magazine, 27 August 2020

Quoted “The needs of the many,” Intellectual Property Magazine, 29 May 2020

Quoted “Editor’s Letter - May 2020,” Intellectual Property Magazine, 1 May 2020

Quoted “Compulsory licensing could create more problems than it solves,” Managing Intellectual Property, 22 April 2020

Quoted “Breaking: EPO revokes Broad’s CRISPR patent,” Life Sciences Intellectual Property Review. 16 January 2020

Quoted “Broad Institute facing tough fight in CRISPR patent appeal hearing,” IAM, 14 January 2020 

Quoted “Should I stay or should I go? Private practice v in-house”, Managing Intellectual Property, 18 September 2019

Quoted “Beware the pay gap: Lawyers who shun an in-house switch”, Managing Intellectual Property, 21 August 2019

Quoted “Precision medicine: The personal touch”, Life Sciences Intellectual Property Review, 21 May 2019

Quoted “UCal granted wide-ranging CRISPR rights, but future patent landscape remains uncertain”, IAM, 30 April 2019

Quoted, “The big life sciences patent news from February”, IAM, 11 March 2018

Quoted, “Locus licenses CRISPR tech to Janssen in potential $818m deal”, Life Sciences Intellectual Property Review, 9 January 2019

Quoted, “Top 10 patent cases of the year”, JUVE Patent, 21 December 2018

Quoted, "Revolutionary change in CRISPR patent landscape poses tough questions for life sciences companies", IAM, 27 July 2018

Quoted, "EPO revokes Broad’s CRISPR patent", Nature Biotechnology, 6 March 2018

Quoted, "European Patent Office revokes Broad Institute CRISPR patent", BioWorld, 19 January 2018

Quoted, "CRISPR opposition hearing kicks off at European Patent Office", AgroNews, 19 January 2018


IAM Strategy 300 — 2020, 2021, 2022

IAM Patent 1000 — 2020, 2021, 2022

World IP Review — WIPR Leaders, 2020, 2021, 2022

Expert Guides — Rising Star: Life Sciences, UK — 2019, 2021

Euromoney Legal Media Group Europe Rising Stars Awards 2019 — Winner — Rising Star: Life Sciences; Rising Star: UK

Managing Intellectual Property IP STARS — Rising Star, 2017, 2018


Memberships & Affiliations

EPLAW – European Patent Lawyers Association 

International Association for the Protection of Intellectual Property (AIPPI)

  • Vice-Chair of Standing Committee on Biotechnology
  • Vice-Chair of Standing Committee on IP and genetic resources/traditional knowledge
  • Member of the UK Group


Admissions & Qualifications

  • 2012, Admitted to the High Court of Australia
  • 2012, Admitted to Practice as a Solicitor of the Supreme Court of New South Wales, Australia


  • University of OxfordPostgraduate Diploma in Intellectual Property Law and PracticeDistinction2016
  • University of SydneyLL.B.First Class Honours2011

    University of Sydney Law Revue

    Minter Ellison Prize for Intellectual Property, 2010

  • University of SydneyB.Sc.First Class Honours2009